Dr. Loretta Que, MD
Pulmonology (Pulmonary Disease Physician)
- Medicare participating
At a glance
- Medical school
- University of Chicago, Pritzker School of Medicine (1989)
- Years since graduation
- 37
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 84
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 1989Medical school: University of Chicago, Pritzker School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
Pulmonary Disease Physician primary
NC license 9601124
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Hospitals
- Duke University Hospital Durham, NC
- Duke Regional Hospital Durham, NC
- Duke Health Lake Norman Hospital Mooresville, NC
Medical groups
- Duke Health Integrated Practice, Inc (3,185 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 84
- Services billed
- 268
- Patients’ average age
- 72
| Service | Times | Patients |
|---|---|---|
| Critical care, first 30-74 minutes | 54 | 21 |
| Established patient office or other outpatient visit, 40-54 minutes | 48 | 42 |
| Established patient office or other outpatient visit, 30-39 minutes | 48 | 44 |
| Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | 24 | 14 |
| Insertion of needle into vein for collection of blood sample | 11 | 11 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
| Drug | Prescriptions |
|---|---|
| Trelegy Ellipta (fluticasone/umeclidin/vilanter) Other prescribers in Durham, NC | 105 |
| Albuterol Sulfate Hfa (albuterol sulfate) Other prescribers in Durham, NC | 53 |
| Montelukast Sodium Other prescribers in Durham, NC | 51 |
| Anoro Ellipta (umeclidinium brm/vilanterol tr) Other prescribers in Durham, NC | 37 |
| Nucala (mepolizumab) | 28 |
| Prednisone Other prescribers in Durham, NC | 26 |
| Omeprazole Other prescribers in Durham, NC | 26 |
| Azithromycin Other prescribers in Durham, NC | 23 |
| Ipratropium Bromide Other prescribers in Durham, NC | 22 |
| Symbicort (budesonide/formoterol fumarate) Other prescribers in Durham, NC | 20 |
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 1 companies reported 4 payments worth $11,300 in total to this clinician.
| Genzyme Corporation | $11,300 |
|---|
| Consulting Fee | $10,127 |
|---|---|
| Travel and Lodging | $1,039 |
| Food and Beverage | $134 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| Genzyme Corporation Nov 21, 2025 | Consulting Fee | $10,127 |
| Genzyme Corporation Nov 11, 2025 | Travel and Lodging travel to Philadelphia, PA · in-kind | $712 |
| Genzyme Corporation Nov 11, 2025 | Travel and Lodging travel to Philadelphia, PA · in-kind | $327 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 5 industry-funded studies in 2025, from 4 companies. The companies reported $298,412 in research payments for these studies, mostly to the institutions running them.
- A Phase 2, Randomized, Double-blind, Placebo-controlled, Dose Ranging Study to Assess the Efficacy and Safety of Rocatinlimab in Adult Subjects With Moderate-to-severe Asthma
Amgen Inc. - IL13 Signaling in Allergic Asthma
Regeneron Pharmaceuticals, Inc. · Completed · NCT05478824 - A Phase III Multicentre Randomised Double blind Chronic dosing Parallel group Placebo controlled Study to Evaluate the Efficacy and Safety of Two Dose Regimens of Tozorakimab in Participants with Symptomatic Chronic O…
AstraZeneca UK Limited - A Phase III, Multicentre, Randomised, Double-blind, Chronic-dosing, Parallel-group, Placebo-controlled Extension Study to Evaluate the Long-term Efficacy and Safety of Tozorakimab (MEDI3506) in Participants with Chron…
AstraZeneca Pharmaceuticals LP - The CHRONICLE Study is a multi center,non interventional,prospective cohort study of adults with severe asthma who do not achieve control with high-dose ICS therapy with additional controllers and or require systemic …
AstraZeneca Pharmaceuticals LP
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.